News
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support ...
GSK PLC GSK shares dropped 2.45% to £15.12 Friday, on what proved to be an all-around poor trading session for the stock ...
4h
Zacks.com on MSNEMA Accepts GSK's Filing for Expanded Use of RSV Vaccine ArexvyGSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
GSK PLC closed 11.51% short of its 52-week high of £16.79, which the company achieved on September 9th.
9h
Pharmaceutical Technology on MSNNICE approves GSK’s belantamab mafodotin for blood cancerNHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.
3d
Pharmaceutical Technology on MSNBharat Biotech acquires licence for GSK’s Shigella vaccine developmentGSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...
Nagpur: A blood donation and health check-up camp was organised on Saturday at the MIDC Industries Association (MIA) premises ...
GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results